The cause of Crohn's disease remains obscure, and treatment unsatisfactory. Much evidence suggests that the expression of immune responses in the gastrointestinal mucosa may be of importance, and evidence for sensitisation of patients to a variety of gut associated antigens, both intrinsic and extrinsic, has been reported.' Surgical diversion of the faecal stream,2 total parental nutrition,3 the use of elemental diets,4 and reduction of bacterial colonisation of the gut,5 have all been reported to be of possible benefit in the treatment of Crohn's disease. Most of these reports have been of uncontrolled trials, which is clearly unsatisfactory in a disease characterised by spontaneous remissions and relapses; furthermore the means of assessing changes in disease activity have sometimes been highly subjective, without objective laboratory evidence of reduction in inflammation. We report here the results of a randomised trial comparing the conventional therapy for Crohn's disease by oral prednisolone (the most beneficial treatment overall in the multicentre United States6 and European trials7) with a regime designed to remove antigens from the gut lumen - After the final assessment, at the time that a normal diet was reinstituted and antibiotics discontinued in group B, patients were treated with prednisolone (10 mg daily) and salazopyrine (if colonic involvement was present).
Results
At admission to the trial active inflammation of the Faecal granulocyte excretion was raised in all patients (normal <2%). Table 2 shows the mean Crohn's Disease Activity Index, the ESR and the faecal granulocyte excretion in patients in both treatment groups, before and after therapy, and full details according to disease distribution are given in Table 1 . Fifteen of 16 patients treated with an elemental diet and non-absorbable antibiotics improved with falls in faecal granulocyte excretion while a single patient deteriorated with a rise in granulocyte excretion ( Fig. 2 Table 2 ). There were concordant changes in the clinical index (CDAI) in 14 out of the 16 patients, including the single patient who deteriorated. The discordant CDAI results were due to alterations in the patients' own assessment of their well being, in one case corresponding to an intercurrent chest infection, and in the other to the development of heartburn. Changes in ESR were also concordant with changes in faecal excretion in 14 of 16 patients; in one patient the ESR rose from 60 to 70 mm in the first hour despite definite improvement on both faecal excretion and CDAI and in one patient the ESR rose from 10 to 11 m/h. Faecal granulocyte excretion and CDAI fell in all 16 patients treated with prednisolone ( Fig. 2 Table  2 ). Erythrocyte sedimentation rate changed concordantly in 15 of the 16 patients, the exception being the patient showing the smallest decrease in faecal granulocyte excretion. The details of the measured indices in the two groups of patients before and after therapy (Table 2) indicate that there were no differences between the levels of any of these parameters between the two groups at admission to the trial. There was a sigificant fall in parameters of disease activity after 10 days in both treatment groups (p<OO1). At the end of the trial there was no significant difference in the levels between parameters of disease activity between the two treatment groups.
Discussion
The course of Crohn's disease is unpredictable, and spontaneous fluctuations in activity are common, indicating the need for controlled evaluation of therapy. Such trials have shown convincing effects of corticosteroids in the treatment of active Crohn's disease both affecting the small intestine and the colon.6 7 The modes of assessment in such trials have been criticised, however, particularly when they have been mainly based on the use of a clinical disease activity index such as the CDAI. This numerical index,9 derived for the purpose of subsequent statistical analysis, is based on surveying eight clinical features to reach a score ranging between 50 and over 450; 23% of the variance of the final value depends upon the patients subjective assessment of his own well being. The method is thus an imperfect tool in evaluating the therapeutic effects of drugs such as corticosteroids which may have prominent euphoriant effects. While laboratory measurements of acute phase reactants, or the sedimentation rate, do reflect mucosal inflammation, they lack specificity for gastrointestinal disease and are easily affected by intercurrent episodes. The technique of l11In-dium scanning, however, with measurement of faecal radioactivity excretion, offers an objective measurement, specific for mucosal inflammation. This study now shows that it is a highly effective means of assessing the effects of drugs in clinical trials, although it is currently technically demanding. As would be expected, some patients with CDAI levels of below 150, usually taken at clinical remission, in fact had raised faecal granulocyte levels.
In the groups of patients surveyed here, all those treated with corticosteroids rapidly improved by both objective and subjective indices of mucosal inflammation. The striking findings was that in a group of 16 patients treated with oral nonabsorbable antibiotics and an elemental diet, there was a statistically indistinguishable improvement in these parameters of inflammation. The progress was assessed after 10 days therapy, although usually the improvement was clinically apparent within a few days of initiation of treatment. The effect of non-absorbable antibiotics and elemental diet was seen both in patients with colonic and those with small intestinal involvement.
There is evidence from others that an approach involving the removal of antigens from the gastrointestinal tract may be effective. The only controlled study, that of O'Morain et allo showed that an elemental diet -without antibiotics -was as effective after 28 days of therapy as corticosteroids in patients with mild or moderately active disease. Responses to total parental nutrition,3 or to nonabsorbable antibiotics, have been reported in other uncontrolled studies.11 The combination of the two used here appears to have a particular advantage in that it worked rapidly suggesting that it may be an appropriate form of therapy for ill patients, avoiding the side effects of corticosteroid therapy.
The use of the antibiotic and elemental diet regime was, however, limited -in nearly a quarter of individuals in whom it was tried -by intolerance. This was mainly in the form of vomiting and nausea induced by the antibiotics. A similar high incidence of non-compliance was seen in the controlled trial of elemental diet.10 In our study such intolerance became clear within two to three days of initiating treatment, and thus can be recognised early without causing significant delay in treatment.
The effectiveness of this regime of nonabsorbable antibiotics and elemental diet is clearly established by this study, as a short term rapid means of treating acute Crohn's disease. The mechanism of improvement -whether by reducing antigens as targets of the host immune response, by removing the invading bacteria which are reported within the mucosa of patients with Crohn's disease12 or by repairing a postulated nutritional defect, remains speculative. The long term outlook of remission induced by this regime also requires to be assessed. In this trial, the reintroduction of a normal diet, and withdrawal of antibiotics, was electively covered with low doses of corticosteroids. Further studies are in process to determine whether this is necessary. 
